Vericel (VCEL) Competitors $36.28 +0.51 (+1.43%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$36.28 -0.01 (-0.01%) As of 08/15/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VCEL vs. LEGN, RVMD, RYTM, RNA, NUVL, ABVX, AXSM, CRSP, MRUS, and VKTXShould you be buying Vericel stock or one of its competitors? The main competitors of Vericel include Legend Biotech (LEGN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Nuvalent (NUVL), Abivax (ABVX), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Merus (MRUS), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical products" industry. Vericel vs. Its Competitors Legend Biotech Revolution Medicines Rhythm Pharmaceuticals Avidity Biosciences Nuvalent Abivax Axsome Therapeutics CRISPR Therapeutics Merus Viking Therapeutics Vericel (NASDAQ:VCEL) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership. Does the media prefer VCEL or LEGN? In the previous week, Legend Biotech had 18 more articles in the media than Vericel. MarketBeat recorded 22 mentions for Legend Biotech and 4 mentions for Vericel. Vericel's average media sentiment score of 1.49 beat Legend Biotech's score of 0.40 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 5 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of VCEL or LEGN? 70.9% of Legend Biotech shares are owned by institutional investors. 5.2% of Vericel shares are owned by company insiders. Comparatively, 0.0% of Legend Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts recommend VCEL or LEGN? Vericel currently has a consensus target price of $60.33, suggesting a potential upside of 66.30%. Legend Biotech has a consensus target price of $72.38, suggesting a potential upside of 93.00%. Given Legend Biotech's higher probable upside, analysts clearly believe Legend Biotech is more favorable than Vericel.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vericel 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Legend Biotech 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is VCEL or LEGN more profitable? Vericel has a net margin of 2.85% compared to Legend Biotech's net margin of -40.83%. Vericel's return on equity of 2.47% beat Legend Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Vericel2.85% 2.47% 1.69% Legend Biotech -40.83%-32.00%-20.07% Which has more volatility & risk, VCEL or LEGN? Vericel has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Which has better earnings and valuation, VCEL or LEGN? Vericel has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVericel$237.22M7.72$10.36M$0.12302.33Legend Biotech$796.84M8.65-$177.03M-$0.88-42.61 SummaryVericel beats Legend Biotech on 9 of the 16 factors compared between the two stocks. Get Vericel News Delivered to You Automatically Sign up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCEL vs. The Competition Export to ExcelMetricVericelMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.83B$3.14B$5.72B$9.79BDividend YieldN/A2.21%3.91%4.13%P/E Ratio302.3621.0331.1425.06Price / Sales7.72324.75434.1997.73Price / Cash116.1042.6136.7858.67Price / Book5.978.659.086.18Net Income$10.36M-$54.65M$3.26B$265.11M7 Day Performance0.11%6.56%7.39%4.22%1 Month Performance0.06%4.82%4.22%0.77%1 Year Performance-21.61%15.81%30.30%24.69% Vericel Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCELVericel2.3025 of 5 stars$36.28+1.4%$60.33+66.3%-21.6%$1.83B$237.22M302.36300LEGNLegend Biotech3.7345 of 5 stars$36.24-2.1%$73.33+102.4%-34.1%$6.80B$627.24M0.002,609News CoverageEarnings ReportAnalyst ForecastRVMDRevolution Medicines4.1756 of 5 stars$34.70-0.9%$68.82+98.3%-15.2%$6.54B$11.58M0.00250News CoverageAnalyst ForecastGap UpRYTMRhythm Pharmaceuticals3.7502 of 5 stars$94.31+2.5%$101.57+7.7%+111.8%$6.11B$130.13M0.00140News CoverageInsider TradeRNAAvidity Biosciences3.1693 of 5 stars$45.75-1.2%$67.00+46.4%+3.3%$5.96B$10.90M0.00190Positive NewsInsider TradeNUVLNuvalent3.3613 of 5 stars$74.95+1.1%$119.60+59.6%+6.3%$5.32BN/A0.0040ABVXAbivax3.5104 of 5 stars$69.00-1.6%$92.33+33.8%+549.2%$5.30BN/A0.0061Short Interest ↑AXSMAxsome Therapeutics4.7401 of 5 stars$103.96-0.8%$178.00+71.2%+26.7%$5.23B$385.69M0.00380CRSPCRISPR Therapeutics3.3521 of 5 stars$55.41+0.7%$71.60+29.2%+24.8%$5.00B$37.31M0.00460MRUSMerus2.0973 of 5 stars$64.60+0.9%$88.50+37.0%+30.2%$4.84B$36.13M0.0037VKTXViking Therapeutics4.0816 of 5 stars$38.20+0.8%$86.92+127.6%-29.4%$4.26BN/A0.0020Positive News Related Companies and Tools Related Companies LEGN Competitors RVMD Competitors RYTM Competitors RNA Competitors NUVL Competitors ABVX Competitors AXSM Competitors CRSP Competitors MRUS Competitors VKTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VCEL) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Vericel With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access